摘要
目的评价Ⅱ/Ⅲ期(DukesB/C期)低位直肠癌术前同步放化疗的疗效。方法对23例Ⅱ/Ⅲ期低位直肠癌患者放疗+同步口服希罗达,4～6周后行手术治疗。结果放化疗后肿瘤缩小,手术切除率为100.0%,保肛率为73.9%,局部复发率仅为4.4%,吻合口瘘的发生率为4.4%。结论对于Ⅱ/Ⅲ期(DukesB/C期)低位直肠癌患者术前同步放化疗可以提高手术切除率、保肛率,降低局部复发率,并不增加术后吻合口瘘的发生,是1种较好的治疗手段。
Objective To evaluate the clinical therapeutic effect for patients with resectable stage Ⅱ/Ⅲ （ Dukes B/C stage） low rectal cancer treated with preoperative concurrent chemoradiotherapy. Methods 23 patients with stage Ⅱ/Ⅲ low rectal cancer were included in this study. Capecitabine was orally administered concurrently with radiotherapy. Surgery was performed 4 -6 weeks after completion of chemoradiotherapy. Results Tumor volume shrank in 21 patients. All patients received radical surgery. The rates of sphincter preservation,local recurrence and anastomotic leakage were 73.9% ,4.4% and 4.4%, respectively. Conclusion Preoperative concurrent chemoradiotherapy with Capecitabine can improve the rate of tumor resection and sphincter preservation in patients with stage Ⅱ/Ⅲ （ Dukes B/C stage） low rectal cancer. It can reduce the local recurrence with a low anastomotic leakage rate.
出处
《实用癌症杂志》
2007年第6期638-640,共3页
The Practical Journal of Cancer
关键词
低位直肠癌
术前同步放化疗
保肛
局部复发
Low rectal cancer
Preoperative concurrent chemoradiotherapy
Sphincter preservation
Local recurrent
